AUS
NZ
UK
CA
USA
IND
Highlights
- Belite Bio progresses Phase 3 DRAGON trial with positive interim analysis of Tinlarebant.
- Data Safety Monitoring Board recommends trial continuation, with no changes to the sample size.
- Tinlarebant demonstrates safety and stability in visual acuity for adolescent Stargardt patients.
Belite Bio (NASDAQ:BLTE) has announced promising interim analysis results from its pivotal Phase 3 DRAGON trial of Tinlarebant in adolescent patients with Stargardt disease. Stargardt disease, a rare inherited retinal disorder, currently has no approved treatments, and this trial could mark a significant breakthrough in managing the condition. The Data Safety Monitoring Board (DSMB) reviewed the results and recommended that the trial proceed without modifications, maintaining the original 104-subject sample size. The trial is expected to reach completion by Q4 2025.
The interim data highlights the favorable profile of Tinlarebant, demonstrating that the drug is well-tolerated among patients, with a consistent safety profile across the study. Visual acuity, a key measure of vision quality, remained stable in the majority of subjects, showing mean changes of less than three letter scores from baseline under both standard and low luminance conditions over the two-year duration of the study. These findings are particularly encouraging for Stargardt disease patients, who often experience a decline in visual function over time.
The DRAGON trial is a randomized, double-masked, placebo-controlled study conducted across 11 jurisdictions, with a 2:1 randomization of active treatment versus placebo. The primary endpoint of the trial is to assess the atrophic lesion growth rate, which is crucial for understanding the progression of Stargardt disease and the potential of Tinlarebant to slow or halt this progression. So far, the results are promising, with no significant safety concerns reported, which bodes well for the potential of Tinlarebant as a viable treatment option.
In addition to the positive interim results, Tinlarebant has received multiple regulatory designations that could expedite its path to commercialization. These include Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA), Orphan Drug status in the U.S., Europe, and Japan, and Pioneer Drug Designation in Japan for Stargardt disease. These designations underscore the unmet need in treating Stargardt disease and could allow Belite Bio to accelerate the development process, bringing much-needed treatment to patients sooner.
While the trial's results to date are positive, the completion of the DRAGON trial is not expected until Q4 2025, meaning that full data on Tinlarebant’s effectiveness will not be available until then. Additionally, the absence of an approved treatment for Stargardt disease means that patients currently lack commercially available options. However, the progress seen in the ongoing trial offers hope for those affected by this debilitating condition.
Overall, Belite Bio's interim results from the DRAGON trial represent a significant step forward in the development of Tinlarebant for Stargardt disease, with the potential to offer a much-needed treatment option for patients suffering from this rare retinal disorder.
